Tissue distribution of crizotinib and gemcitabine combination in a patient-derived orthotopic mouse model of pancreatic cancer
Pharmacokinetics focuses on the question whether a drug actually reaches its target in therapeutic concentrations or accumulates elsewhere, potentially causing toxicological or unpredictable side effects. We determined tissue distribution of gemcitabine, an antimetabolite, and crizotinib, a tyrosine...
Main Authors: | Richard J. Honeywell, Amir Avan, Elisa Giovannetti, Godefridus J. Peters |
---|---|
Format: | Article |
Language: | English |
Published: |
International Association of Physical Chemists (IAPC)
2016-12-01
|
Series: | ADMET and DMPK |
Subjects: | |
Online Access: | http://pub.iapchem.org/ojs/index.php/admet/article/view/335 |
Similar Items
-
Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer
by: Daniela Massihnia, et al.
Published: (2017-01-01) -
The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model
by: Takashi Higuchi, et al.
Published: (2019-03-01) -
In vivo real-time imaging of gemcitabine-leaded growth inhibition in the orthotopic transplantation model of human pancreatic tumor
by: Sheng-hua Zhang, et al.
Published: (2011-12-01) -
LY293111 Improves Efficacy of Gemcitabine Therapy on Pancreatic Cancer in a Fluorescent Orthotopic Model in Athymic Mice
by: Rene Hennig, et al.
Published: (2005-04-01) -
The role of brigatinib in crizotinib-resistant non-small cell lung cancer
by: Mezquita L, et al.
Published: (2018-01-01)